Lilly Executive and Leadership Team

Pandurang Kulkarni, the Chief Executive Officer, Aparito (Subsidiary of Eli Lilly) & Research Development Chief Analytics Officer & Senior VP, Stats, Data & Analytics at Lilly, directs the integration of advanced data science into biopharmaceutical research. Kulkarni architects complex statistical frameworks that accelerate drug discovery cycles while overseeing the digital transformation of clinical trial monitoring. By leveraging real-world evidence, the Research Development Chief Analytics Officer optimizes patient outcome tracking across international markets. This leadership role requires constant collaboration with global R&D teams to ensure data integrity and regulatory compliance. Pandurang Kulkarni drives the adoption of machine learning models to predict therapeutic efficacy, ultimately reducing time-to-market for critical medications. Through the application of sophisticated analytics, the Senior VP, Stats, Data & Analytics secures a competitive advantage for the firm in the highly regulated pharmaceutical landscape, ensuring that data-driven insights inform every stage of the development pipeline.

Miyuki Ashida, the Director, Research & Development & Chief Operating Officer, Project Management at Lilly, manages the operational execution of complex drug development programs. Ashida coordinates cross-functional teams to streamline project timelines, ensuring that research milestones align with corporate commercialization goals. By implementing rigorous project management methodologies, the Chief Operating Officer, Project Management eliminates bottlenecks in the transition from laboratory discovery to clinical trials. This role involves frequent interaction with senior leadership to allocate resources effectively across the global R&D portfolio. Miyuki Ashida drives efficiency in the development of prescription medicines, focusing on therapeutic areas like oncology and immunology. Through meticulous oversight of project lifecycles, the Director, Research & Development maintains high standards of operational excellence. Ashida ensures that every phase of the research process adheres to strict quality benchmarks, ultimately supporting the rapid delivery of life-saving treatments to patients worldwide.

LisaAnn Trembath, the Chief Operating Officer, Global Imaging at Lilly, oversees the operational infrastructure supporting diagnostic imaging technologies within the biopharmaceutical framework. Trembath directs the integration of imaging solutions into clinical research, ensuring that data collection meets the highest standards for regulatory approval. By managing global supply chains and technical partnerships, the Chief Operating Officer, Global Imaging optimizes the deployment of diagnostic tools across international research sites. This role involves coordinating with medical affairs and R&D departments to enhance the precision of clinical trial endpoints. LisaAnn Trembath drives operational scalability, allowing the firm to conduct large-scale studies with greater accuracy. Through the implementation of advanced imaging protocols, the Chief Operating Officer, Global Imaging supports the development of targeted therapies in oncology and immunology. Trembath ensures that imaging operations remain agile, providing the necessary technical support to advance the company's mission of delivering innovative prescription medicines to patients.

Wayne Russo, the LoxoLilly Field Chief Operating Officer at Lilly, manages the execution of field-based commercial operations for the oncology division. Russo directs regional sales and support teams to ensure that specialized cancer therapies reach healthcare providers efficiently. By optimizing field force deployment, the LoxoLilly Field Chief Operating Officer enhances the delivery of medical information and product support to oncology centers. This leadership role requires constant monitoring of market dynamics to adjust operational strategies in real-time. Wayne Russo drives performance across North American and international markets, ensuring that field operations align with the broader corporate strategy for oncology growth. Through the management of complex logistics and stakeholder relationships, the LoxoLilly Field Chief Operating Officer maintains high levels of service quality. Russo executes initiatives that improve patient access to innovative oncology treatments, ultimately supporting the company's goal of transforming cancer care through research-driven innovation and effective field-based execution.

Brandi Doyle, the Vice President and COO- Lilly Cardiometabolic Health Development at Lilly, directs the operational strategy for the company's cardiometabolic research and development pipeline. Doyle architects the clinical development plans for diabetes and cardiovascular therapies, ensuring that research programs meet rigorous safety and efficacy standards. By overseeing resource allocation and cross-functional collaboration, the COO- Lilly Cardiometabolic Health Development accelerates the progression of new molecules from early-stage research to late-stage clinical trials. This role involves frequent engagement with regulatory bodies to facilitate the approval of life-changing medications. Brandi Doyle drives operational efficiency across global development teams, focusing on the unique needs of patients with chronic metabolic conditions. Through strategic oversight of the development lifecycle, the Vice President and COO- Lilly Cardiometabolic Health Development ensures that the cardiometabolic portfolio remains a cornerstone of the company's growth. Doyle executes complex development strategies that address the urgent global demand for effective diabetes and cardiovascular treatments.

Ahmed Abdelkhalek, the Assistant Vice President & Chief Marketing Officer & Chief Operating Officer, Meta Region at Lilly, directs the commercial and operational activities across the Middle East, Turkey, and Africa. Abdelkhalek architects regional marketing strategies that adapt global pharmaceutical brands to local market requirements. By managing the operational footprint in the Meta Region, the Chief Operating Officer, Meta Region ensures that supply chains and distribution networks function effectively to meet patient demand. This leadership role requires balancing regional regulatory compliance with the need for rapid market penetration. Ahmed Abdelkhalek drives growth by fostering partnerships with local healthcare systems and government entities. Through the integration of marketing and operational functions, the Assistant Vice President & Chief Marketing Officer & Chief Operating Officer, Meta Region optimizes the delivery of prescription medicines to diverse patient populations. Abdelkhalek executes regional initiatives that strengthen the company's presence, ensuring that innovative therapies reach patients in emerging markets efficiently.

Stephanie Brennan, the Global Chief Operating Officer, Medical Affairs, Immunology Heor at Lilly, directs the operational framework for medical affairs and health economics and outcomes research within the immunology division. Brennan architects the processes that translate clinical data into actionable insights for healthcare providers and payers. By overseeing the dissemination of scientific evidence, the Global Chief Operating Officer, Medical Affairs, Immunology Heor ensures that the value of immunological therapies is clearly communicated to the medical community. This role involves coordinating with global research teams to support the development of robust evidence packages. Stephanie Brennan drives the integration of HEOR data into commercial strategies, facilitating better patient access to innovative treatments. Through the management of medical affairs operations, the Global Chief Operating Officer, Medical Affairs, Immunology Heor maintains high standards of scientific integrity. Brennan executes initiatives that demonstrate the long-term clinical and economic benefits of the company's immunology portfolio, supporting the firm's mission of improving patient outcomes.

Marija Popovic, the Global Chief Operating Officer, Statistical Sciences & Advanced Analytics at Lilly, directs the operational infrastructure for the company's statistical and analytical functions. Popovic architects the workflows that enable the processing of massive clinical datasets, ensuring that statistical rigor underpins every research decision. By managing the global team of data scientists and statisticians, the Global Chief Operating Officer, Statistical Sciences & Advanced Analytics optimizes the use of advanced modeling techniques in drug development. This leadership role requires close collaboration with R&D and regulatory teams to ensure that analytical outputs meet the highest standards for clinical trial submissions. Marija Popovic drives the adoption of innovative statistical methodologies that improve the speed and accuracy of clinical research. Through the oversight of analytical operations, the Global Chief Operating Officer, Statistical Sciences & Advanced Analytics supports the development of precision medicines. Popovic executes strategies that leverage data to solve complex biological challenges, ultimately advancing the company's research-driven mission.

Roberto Servi, the Global Senior VP, Marketing & Chief Marketing Officer, Neuroscience Business Unit at Lilly, architects the commercial strategy for the company's neuroscience portfolio. Servi directs global marketing initiatives that position innovative therapies within competitive international markets. By analyzing patient needs and physician feedback, the Chief Marketing Officer, Neuroscience Business Unit develops targeted campaigns that increase awareness of complex neurological conditions. This leadership position requires close alignment with clinical development teams to ensure that marketing messaging reflects the latest scientific advancements. Roberto Servi drives revenue growth by expanding market access and strengthening relationships with healthcare providers across diverse regions. Through strategic brand management, the Global Senior VP, Marketing ensures that the neuroscience division maintains a dominant market position. Servi executes comprehensive launch plans for new medications, consistently focusing on improving patient access to essential treatments while maximizing the long-term value of the neuroscience product pipeline.

Christina Vega, the VP-Head of Immunology, Oncology, and Neuroscience Division and Chief Marketing Officer at Lilly, directs the strategic commercial direction for three of the company's most critical therapeutic areas. Vega architects the marketing and brand strategies that drive the adoption of innovative therapies in immunology, oncology, and neuroscience. By overseeing the commercial lifecycle of these products, the Chief Marketing Officer ensures that the company's portfolio addresses the most pressing needs of patients worldwide. This leadership role involves coordinating with global R&D and medical affairs to align commercial goals with scientific breakthroughs. Christina Vega drives market expansion by identifying new therapeutic opportunities and strengthening the company's competitive position. Through the management of these diverse divisions, the VP-Head of Immunology, Oncology, and Neuroscience Division and Chief Marketing Officer maintains a focus on delivering high-value prescription medicines. Vega executes comprehensive commercial plans that support the company's long-term growth and commitment to improving patient health through research-driven innovation.